Egrifta
Showing 1 - 9 of 9
Peripheral Nerve Injuries Trial in Baltimore (Tesamorelin 2 Milligrams (MG), Placebo)
Recruiting
- Peripheral Nerve Injuries
- Tesamorelin 2 Milligrams (MG)
- Placebo
-
Baltimore, MarylandSami Tuffaha
Dec 7, 2021
HIV Lipodystrophy Syndrome, Growth Hormone Deficiency, Body Composition Trial in New York (Tesamorelin)
Recruiting
- HIV Lipodystrophy Syndrome
- +2 more
-
New York, New YorkNeuroendocrine Unit and Pituitary Center, Columbia University
Jul 12, 2021
Lipodystrophy, HIV Trial in Worldwide (Tesamorelin, Placebo for Tesamorelin)
Completed
- Lipodystrophy
- HIV Infections
- Tesamorelin
- Placebo for Tesamorelin
-
Birmingham, Alabama
- +46 more
Sep 16, 2022
Human Immunodeficiency Virus (HIV), Nonalcoholic Fatty Liver Disease (NAFLD), Nonalcoholic Steatohepatitis (NASH) Trial in
Completed
- Human Immunodeficiency Virus (HIV)
- +2 more
- tesamorelin
- Placebo
-
Bethesda, Maryland
- +1 more
Jan 13, 2020
Mild Cognitive Impairment Trial in Galveston (Growth Hormone Releasing Hormone (GHRH), Placebo Growth Hormone Releasing Hormone)
Completed
- Mild Cognitive Impairment
- Growth Hormone Releasing Hormone (GHRH)
- Placebo Growth Hormone Releasing Hormone
-
Galveston, TexasThe University of Texas Medical Branch
Nov 1, 2019
HIV Subjects Exposed to EGRIFTA®
Terminated
- HIV
- Tesamorelin for injection
-
Bakersfield, California
- +30 more
Sep 10, 2018
HIV, HIV Lipodystrophy Trial in Boston (tesamorelin, )
Completed
- HIV
- HIV Lipodystrophy
- tesamorelin
- placebo
-
Boston, MassachusettsMassachusetts General Hospital
Sep 28, 2017
Egrifta Replacement and Sleep Disordered Breathing
Withdrawn
- Lipodystrophy
- Tesamorelin (Egrifta)
-
Baltimore, MarylandJohns Hopkins Sleep Disorders Center
Mar 2, 2017